Armata Pharmaceuticals Valuation
| ARMP Stock | USD 8.15 0.09 1.09% |
At this time, the firm appears to be undervalued. Armata Pharmaceuticals shows a prevailing Real Value of $9.75 per share. The current price of the firm is $8.15. Our model approximates the value of Armata Pharmaceuticals from analyzing the firm fundamentals such as Operating Margin of (6.71) %, shares outstanding of 36.41 M, and Return On Equity of -34.39 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Armata Pharmaceuticals' valuation include:
Price Book 2.1095 | Enterprise Value | Enterprise Value Ebitda 15.7239 | Price Sales 58.7092 | Enterprise Value Revenue 148.1376 |
Undervalued
Today
Please note that Armata Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of Armata Pharmaceuticals is based on 3 months time horizon. Increasing Armata Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Armata Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 8.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.15 | Real 9.75 | Target 12.0 | Hype 8.31 |
The intrinsic value of Armata Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Armata Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Armata Pharmaceuticals helps investors to forecast how Armata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Armata Pharmaceuticals more accurately as focusing exclusively on Armata Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Armata Pharmaceuticals' intrinsic value based on its ongoing forecasts of Armata Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Armata Pharmaceuticals' closest peers.
Armata Pharmaceuticals Cash |
|
Armata Pharmaceuticals Total Value Analysis
Armata Pharmaceuticals is presently expected to have valuation of 462.92 M with market capitalization of 296.72 M, debt of 126.52 M, and cash on hands of 36.98 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Armata Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
462.92 M | 296.72 M | 126.52 M | 36.98 M |
Armata Pharmaceuticals Investor Information
About 69.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.66. Armata Pharmaceuticals last dividend was issued on the 10th of May 2019. The entity had 1:14 split on the 10th of May 2019. Based on the key indicators related to Armata Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Armata Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Armata Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Armata Pharmaceuticals has an asset utilization ratio of 5.99 percent. This connotes that the Company is making $0.0599 for each dollar of assets. An increasing asset utilization means that Armata Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Armata Pharmaceuticals Profitability Analysis
Based on Armata Pharmaceuticals' profitability indicators, Armata Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Armata Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 1993-03-31 | Previous Quarter -16.3 M | Current Value -26.7 M | Quarterly Volatility 8.2 M |
For Armata Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Armata Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Armata Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Armata Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Armata Pharmaceuticals over time as well as its relative position and ranking within its peers.
Armata Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Armata Pharmaceuticals is estimated to be -0.2725 with future projections ranging from a low of -0.2725 to a high of -0.2725. Armata Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -1.66. Please be aware that the consensus of earnings estimates for Armata Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Armata Pharmaceuticals Earnings Estimation Breakdown
The calculation of Armata Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Armata Pharmaceuticals is estimated to be -0.2725 with the future projection ranging from a low of -0.2725 to a high of -0.2725. Please be aware that this consensus of annual earnings estimates for Armata Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.27 Lowest | Expected EPS | -0.27 Highest |
Armata Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Armata Pharmaceuticals' value are higher than the current market price of the Armata Pharmaceuticals stock. In this case, investors may conclude that Armata Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Armata Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 2 | 43.04% | 0.0 | -0.2725 | -1.66 |
Armata Pharmaceuticals Ownership Allocation
Armata Pharmaceuticals holds a total of 36.41 Million outstanding shares. Armata Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 69.12 percent of Armata Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Armata Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 5.17 M. Net Loss for the year was (18.92 M) with loss before overhead, payroll, taxes, and interest of (21.04 M).About Armata Pharmaceuticals Valuation
The stock valuation mechanism determines Armata Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Armata Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Armata Pharmaceuticals. We calculate exposure to Armata Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Armata Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -26.3 M | -25 M | |
| Pretax Profit Margin | (4.20) | (4.41) | |
| Operating Profit Margin | (9.43) | (9.90) | |
| Net Loss | (4.20) | (4.41) | |
| Gross Profit Margin | (6.50) | (6.18) |
Armata Pharmaceuticals Current Valuation Indicators
Armata Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Armata Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Armata Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Armata Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Armata Pharmaceuticals' worth.Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.